文献速递前列腺癌

遗传风险评估及其在诊断性前列腺穿刺活检预测前列腺癌中的临床效用

Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-03-28

本整合性综述评估前列腺癌胚系变异的临床有效性,并探讨其预测前列腺穿刺活检检出率的效用。基于英国生物银行队列示例,家族史、四个基因的罕见致病突变及高遗传风险评分分别识别出8.12%、1.61%和17.38%的男性处于前列腺癌风险升高,风险比分别为1.84、2.74和2.39。综述指出,三种遗传风险指标在前列腺癌风险分层中具有互补性能,但其预测活检检出率的临床效用尚需前瞻性临床试验确认。

要点

  • 基于单核苷酸多态性的遗传风险评分和四个基因的罕见致病突变与前列腺癌风险显著且一致相关。
  • 在英国生物银行中,高遗传风险评分(>1.5)识别出17.38%的男性处于风险升高,风险比为2.39。
  • 遗传风险评分预测前列腺穿刺活检检出率的性能在多项经直肠超声活检队列的回顾性分析中得到一致支持。

核心结论

  • 三种遗传风险指标在前列腺癌风险分层中的互补性能得到一致支持。
  • 若在前瞻性临床试验中得到确认,其预测前列腺穿刺活检检出率的临床效用可能改善当前的前列腺穿刺决策。

研究设计与样本

  • 整合性综述,综合2016年以来已发表的前列腺癌胚系研究,涵盖风险相关单核苷酸多态性、多基因风险评分方法如遗传风险评分及罕见致病突变。
  • 以英国生物银行大型人群队列为例展示研究发现,并基于某医疗系统经验识别临床实施遗传风险评估的差距。

主要发现

  • 在英国生物银行中,阳性家族史、四个基因(HOXB13、BRCA2、ATM和CHEK2)的罕见致病突变及高遗传风险评分(>1.5)分别识别出8.12%、1.61%和17.38%的男性处于前列腺癌风险升高,风险比分别为1.84、2.74和2.39。
  • 遗传风险评分预测前列腺穿刺活检检出率的性能在多项经直肠超声活检队列的回顾性分析中得到一致支持。

关键数值与推荐

  • 阳性家族史识别8.12%的男性处于前列腺癌风险升高,风险比为1.84。
  • 四个基因(HOXB13、BRCA2、ATM和CHEK2)的罕见致病突变识别1.61%的男性处于前列腺癌风险升高,风险比为2.74。
  • 高遗传风险评分(>1.5)识别17.38%的男性处于前列腺癌风险升高,风险比为2.39。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 评估三种遗传指标预测当代多参数磁共振成像引导活检检出率性能的前瞻性研究尚缺乏。
  • 需开展多中心胚系活检试验以填补现有差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many studies on prostate cancer (PCa) germline variants have been published in the last 15 years. This review critically assesses their clinical validity and explores their utility in prediction of PCa detection rates from prostate biopsy. METHODS: An integrative review was performed to (1) critically synthesize findings on PCa germline studies from published papers since 2016, including risk-associated single nucleotide polymorphisms (SNPs), polygenic risk score methods such as genetic risk score (GRS), and rare pathogenic mutations (RPMs); (2) exemplify the findings in a large population-based cohort from the UK Biobank (UKB); (3) identify gaps for implementing inherited risk assessment in clinic based on experience from a healthcare system; (4) evaluate available GRS data on their clinical utility in predicting PCa detection rates from prostate biopsies; and (5) describe a prospective germline-based biopsy trial to address existing gaps. RESULTS: SNP-based GRS and RPMs in four genes (HOXB13, BRCA2, ATM, and CHEK2) were significantly and consistently associated with PCa risk in large well-designed studies. In the UKB, positive family history, RPMs in the four implicated genes, and a high GRS (>1.5) identified 8.12%, 1.61%, and 17.38% of men to be at elevated PCa risk, respectively, with hazard ratios of 1.84, 2.74, and 2.39, respectively. Additionally, the performance of GRS for predicting PCa detection rate on prostate biopsy was consistently supported in several retrospective analyses of transrectal ultrasound (TRUS)-biopsy cohorts. Prospective studies evaluating the performance of all three inherited measures in predicting PCa detection rate from contemporary multiparametric MRI (mpMRI)-based biopsy are lacking. A multicenter germline-based biopsy trial to address these gaps is warranted. CONCLUSIONS: The complementary performance of three inherited risk measures in PCa risk stratification is consistently supported. Their clinical utility in predicting PCa detection rate, if confirmed in prospective clinical trials, may improve current decision-making for prostate biopsy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Xu J, Resurreccion WK, Shi Z, et al. Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer Prostatic Dis. 2022. PMID: 35347252. doi:10.1038/s41391-021-00458-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。